Vascular closure device provider Cardiva Medical announced that the company has closed on $11 million in additional financing – bringing total equity and debt financing in the current round to $41 million. The additional financing exceeds previous commitments for this round and includes returning equity and debt investors – including PTV Healthcare Capital, Canepa Healthcare, and affiliates of Luther King Capital Management.

The U.S. Food and Drug Administration (FDA) issued the final rule on “Human Subject Protection; Acceptance of Data from Clinical Investigations for Medical Devices.” The rule updates the FDA’s standards for accepting clinical data from clinical investigations conducted both inside and outside the United States to help ensure the protection of human participants, and to help ensure the quality and integrity of data obtained from these clinical investigations.

Corindus Vascular Robotics Inc. announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use of its CorPath GRX System in peripheral vascular interventions. The CorPath System is the first and only FDA-cleared medical device, according to the company, to bring robotic precision to both percutaneous coronary intervention (PCI) and peripheral vascular intervention (PVI) procedures.

Society of Cardiovascular Computed Tomography (SCCT)

American Society of Echocardiography (ASE)

Healthcare Information and Management Systems Society (HIMSS)

Deep learning startup company Aidoc announced what it calls the world’s first and only comprehensive, full-body solution utilizing artificial intelligence (AI) to help analyze computed tomography (CT) scans, highlighting medical findings for radiologists. The workflow-integrated solution offers support for radiologists covering areas such as the head, c-spine, chest and abdomen.

An example of Siemens' syngo CTO navigation technology that fuses computed tomogragraphy (CT) imaging with live angiography to help navigate vessel segments that are occluded and not visible on angiography alone.

One of the recent hot topics in interventional cardiology has been how operators can use new tools and techniques to treat coronary chronic total occlusions (CTOs). This was a big area of discussion at both the 2017 American College of Cardiology (ACC) and Transcatheter Cardiovascular Therapeutics (TCT) meetings, and has been the focus of several standalone seminars sponsored by the Cardiovascular Reseach Foundation (CRF). 

February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commencement of its clinical trial and first patient enrollment.  These clinical studies are designed to measure the safety and effectiveness of the HeartSentry technology for cardiovascular health diagnosis.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now